Blood cell-free DNA (cfDNA) testing can be useful before cancer develops, in healthy people. This is the conclusion of the study published in the peer-reviewed scientific journal Cell Death & Disease by an international group of experts, coordinated by Bioscience Genomics, a research entity formed by the collaboration between the University of Rome Tor Vergata and Bioscience Institute, a genomics excellence center already selling the test under the name of HELIXAFE.

Page 5 of 32